Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
LYBREL vs AFIRMELLE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Combination of levonorgestrel and ethinyl estradiol: suppression of gonadotropins (FSH and LH) via negative feedback, inhibiting ovulation; thickening of cervical mucus to impede sperm penetration; alteration of endometrium to reduce implantation likelihood.
Combination oral contraceptive containing ethinyl estradiol and levonorgestrel. Inhibits ovulation by suppressing gonadotropin release (FSH and LH). Also increases cervical mucus viscosity and alters endometrial receptivity.
Prevention of pregnancy
Prevention of pregnancy (FDA-approved)
One tablet (levonorgestrel 0.1 mg/ethinyl estradiol 0.02 mg) orally once daily for 21 days, followed by 7 placebo tablets for 28-day cycle.
One tablet (0.1 mg levonorgestrel, 0.02 mg ethinyl estradiol) orally once daily for 21 days, followed by 7 days of placebo.
Terminal elimination half-life: 27 ± 8 hours; requires ~5 days to reach steady-state; clinical significance: missed doses lead to rapid loss of contraceptive efficacy.
Terminal elimination half-life: 12–15 hours. Steady-state achieved within 5 days with Q12H dosing.
Levonorgestrel: primarily metabolized via reduction, hydroxylation, and conjugation; CYP3A4 involvement. Ethinyl estradiol: metabolized by CYP3A4 and undergoes glucuronidation and sulfation.
Ethinyl estradiol undergoes first-pass metabolism in gut and liver via CYP3A4, with conjugation to sulfate and glucuronide. Levonorgestrel is metabolized primarily by CYP3A4 to reduced and hydroxylated metabolites, then conjugated.
Renal: 50-60% as metabolites, ~20% as parent drug; fecal: 30-40%; biliary: 10-20%.
Renal: 50% as unchanged drug and metabolites; fecal: 40% as metabolites; biliary: ~10% as glucuronide conjugates.
99% bound to albumin and sex hormone-binding globulin (SHBG).
~99% bound to serum albumin and sex hormone-binding globulin.
Vd: 1.7 ± 0.3 L/kg; indicates extensive tissue distribution (e.g., reproductive organs, liver).
2.8 L/kg (apparent Vd), indicating extensive tissue distribution.
Oral: 88% (range 80-95%); first-pass metabolism reduces systemic exposure by ~12%.
Oral: ~70% due to first-pass metabolism.
No dose adjustment required for mild to moderate renal impairment. Not studied in severe renal impairment (GFR <30 m L/min); use not recommended.
No dose adjustment required for mild to moderate renal impairment. Not recommended for use in end-stage renal disease.
Contraindicated in Child-Pugh class B and C hepatic impairment. Use with caution in Child-Pugh class A; monitor liver function.
Contraindicated in acute hepatic disease or severe (Child-Pugh C) hepatic impairment. Use with caution in mild to moderate hepatic impairment; monitor liver function.
Safety and efficacy not established in postmenarchal pediatric patients for oral contraception. Use same dosing as adults for appropriate indications.
Not indicated for use before menarche. Post-menarche: same as adult dosing (one tablet daily) based on adult clinical trials.
Not indicated for use in postmenopausal women; no age-specific data.
Not indicated for use in postmenopausal women; no specific dose adjustment required in healthy elderly, but limited data available.
Cigarette smoking increases risk of serious cardiovascular events from combination oral contraceptive use. Risk increases with age (especially in women >35 years) and with number of cigarettes smoked. Women who use oral contraceptives should be strongly advised not to smoke.
Cigarette smoking increases risk of serious cardiovascular events from combination oral contraceptive use. Risk increases with age (especially in women over 35) and with heavy smoking (15+ cigarettes/day). Women who use combination hormonal contraceptives should be strongly advised not to smoke.
Thrombotic disorders and cardiovascular events (especially in smokers >35 years),Elevated blood pressure,Gallbladder disease,Hepatic neoplasia,Glucose intolerance,Hereditary angioedema,Chloasma,Ocular changes (e.g., retinal thrombosis) requiring discontinuation
Thrombotic disorders (venous thromboembolism, stroke, myocardial infarction),Cigarette smoking (increases cardiovascular risk),Hypertension (especially in women with renal disease or migraines),Gallbladder disease,Hepatic neoplasia (benign and malignant),Carbohydrate and lipid metabolism effects,Ocular lesions (retinal thrombosis),Depressed mood or depression,Uterine bleeding irregularities,Reduced efficacy with hepatic enzyme inducers
Renal or hepatic impairment,Known or suspected pregnancy,Undiagnosed abnormal uterine bleeding,History of or current thromboembolic disorders (e.g., DVT, PE),Cerebrovascular or coronary artery disease,Known or suspected breast carcinoma,Estrogen-dependent neoplasia,Active liver disease (e.g., acute viral hepatitis),Hypersensitivity to any component
Thrombophlebitis or thromboembolic disorders (current or history),Cerebrovascular or coronary artery disease (current or history),Known or suspected breast cancer, endometrial cancer, or other estrogen-dependent neoplasia,Undiagnosed abnormal genital bleeding,Cholestatic jaundice of pregnancy or jaundice with prior oral contraceptive use,Hepatic adenoma or carcinoma (current or history),Known or suspected pregnancy,Hypersensitivity to any component of the product,Heavy smoking (≥15 cigarettes/day) in women over 35
No specific foods are known to interact with Lybrel. Grapefruit juice may slightly increase ethinyl estradiol levels but effect is not clinically significant. Avoid St. John's wort as it may reduce contraceptive efficacy.
Grapefruit juice may increase ethinyl estradiol levels; avoid large quantities. No significant food restrictions. Administer with food if GI upset occurs.
Combined hormonal contraceptives (CHCs) like Lybrel (levonorgestrel/ethinyl estradiol) are contraindicated in pregnancy due to potential fetal harm. First trimester exposure is associated with a slightly increased risk of congenital anomalies, particularly cardiovascular and limb defects, though absolute risk is low. Second and third trimester exposure may lead to adverse outcomes including fetal growth restriction, preterm birth, and neonatal withdrawal symptoms. Data from observational studies suggest no major teratogenic risk at typical contraceptive doses, but use is not recommended once pregnancy is confirmed.
Pregnancy category X. Contraindicated in pregnancy due to risk of fetal harm. First trimester: exposure associated with congenital anomalies (e.g., cardiovascular, neural tube defects). Second and third trimesters: increased risk of fetal growth restriction, preterm birth, and neonatal respiratory distress. Postnatal: possible long-term developmental effects.
Small amounts of ethinyl estradiol and levonorgestrel are excreted in breast milk. The M/P ratio for ethinyl estradiol is approximately 0.05-0.1; for levonorgestrel, it is about 0.1-0.3. Combined hormonal contraceptives may reduce milk production and composition, especially in early postpartum period. Lybrel is not recommended during breastfeeding until weaning, or for at least 6 months postpartum if breastfeeding is established. Progestin-only contraceptives are preferred.
Contraindicated during breastfeeding. Small amounts of ethinyl estradiol and norethindrone are excreted in breast milk; M/P ratio not well defined. Potential for adverse effects on infant (e.g., jaundice, breast enlargement). May reduce milk production and quality.
Lybrel is contraindicated in pregnancy; no dose adjustment is indicated as it should be discontinued immediately upon pregnancy diagnosis. Pharmacokinetic changes in pregnancy (e.g., increased clearance of ethinyl estradiol and levonorgestrel) are not relevant as the drug is not used therapeutically during pregnancy.
Contraindicated in pregnancy; no dose adjustment recommended. If exposure occurs, immediate discontinuation is required. No pharmacokinetic data support safe use; avoid use entirely.
Lybrel is a continuous combined oral contraceptive (COC) containing levonorgestrel 90 mcg and ethinyl estradiol 20 mcg, designed to eliminate monthly withdrawal bleeding. It is taken daily without placebo pills. Breakthrough bleeding and spotting are common in the first 6–12 months. Patients should be counseled that amenorrhea may take up to a year to achieve. Lybrel does not protect against STIs. It is contraindicated in smokers over 35, hypertension (≥160/100 mm Hg), migraine with aura, and thromboembolic disorders. Drug interactions with CYP3A4 inducers (e.g., rifampin, carbamazepine, St. John's wort) may reduce efficacy.
Afirmelle (levonorgestrel/ethinyl estradiol) is a combined oral contraceptive. Counsel patients to take at the same time daily to maintain consistent hormone levels. Use back-up contraception if a dose is missed. Monitor for signs of thromboembolism, especially in smokers over 35. Advise that certain antibiotics (e.g., rifampin) and anticonvulsants (e.g., phenytoin) may reduce efficacy. Consider progestin-only pill if contraindications to estrogen exist.
Take one pill every day at the same time, with or without food. There are no placebo pills, so you will take an active pill daily.,You may experience irregular bleeding or spotting, especially during the first 6–12 months. This is normal and usually decreases over time.,Do not expect a regular menstrual period. Most women will have no bleeding after one year of use.,If you miss pills, follow the package instructions. Missing pills increases the risk of pregnancy and may cause bleeding.,Use a backup method of contraception (like condoms) if you miss two or more pills or start a new pack late.,This medication does not protect against HIV or other sexually transmitted infections.,Tell your healthcare provider if you have new or severe headaches, chest pain, leg pain, vision changes, or jaundice.,Do not smoke while taking this medication, as smoking increases the risk of serious cardiovascular side effects.,Inform all healthcare providers that you are taking Lybrel, especially before surgery or blood tests.,Store at room temperature away from moisture and heat.
Take one pill at the same time every day, even if you don't have sex.,If you miss a pill, follow the instructions in the package insert or ask your healthcare provider.,Use a backup method (like condoms) if you start late or miss pills.,This medication does not protect against HIV or other sexually transmitted infections.,Common side effects include nausea, breast tenderness, and breakthrough bleeding.,Seek medical help if you have symptoms of a blood clot: sudden chest pain, leg swelling, or shortness of breath.,Smoking while on this pill increases your risk of serious cardiovascular events.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about LYBREL vs AFIRMELLE, answered by our medical review team.
LYBREL is a Oral Contraceptive that works by Combination of levonorgestrel and ethinyl estradiol: suppression of gonadotropins (FSH and LH) via negative feedback, inhibiting ovulation; thickening of cervical mucus to impede sperm penetration; alteration of endometrium to reduce implantation likelihood.. AFIRMELLE is a Combined Oral Contraceptive that works by Combination oral contraceptive containing ethinyl estradiol and levonorgestrel. Inhibits ovulation by suppressing gonadotropin release (FSH and LH). Also increases cervical mucus viscosity and alters endometrial receptivity.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between LYBREL and AFIRMELLE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of LYBREL is: One tablet (levonorgestrel 0.1 mg/ethinyl estradiol 0.02 mg) orally once daily for 21 days, followed by 7 placebo tablets for 28-day cycle.. The standard adult dose of AFIRMELLE is: One tablet (0.1 mg levonorgestrel, 0.02 mg ethinyl estradiol) orally once daily for 21 days, followed by 7 days of placebo.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between LYBREL and AFIRMELLE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. LYBREL is classified as Category C. Combined hormonal contraceptives (CHCs) like Lybrel (levonorgestrel/ethinyl estradiol) are contraindicated in pregnancy due to potential fetal harm. First trimester exposure is ass. AFIRMELLE is classified as Category C. Pregnancy category X. Contraindicated in pregnancy due to risk of fetal harm. First trimester: exposure associated with congenital anomalies (e.g., cardiovascular, neural tube defe. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.